Theranostics 2022, Vol. 12, Issue 13

Research Paper

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma

Julia Schmitt1, Johannes Schwenck1,2,10, Andreas Maurer1,10, Mirko Przybille1, Dominik Sonanini3, Gerald Reischl1,10, Jöri E. Wehrmüller1, Leticia Quintanilla-Martinez5,9,10, Stephen D. Gillies6, Marcel A. Krueger1, Juergen F. Schaefer7, Christian la Fougère2,9,10, Rupert Handgretinger8,9,10, Bernd J. Pichler1,9,10

1. Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany
2. Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University Tuebingen, Germany
3. Department of Internal Medicine VIII, Eberhard Karls University Tuebingen, Germany
4. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
5. Institute of Pathology and Neuropathology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Germany
6. Provenance Biopharmaceuticals Corp., Carlisle, MA, USA
7. Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tuebingen, Germany
8. Childrens Hospital, Department of Hematology and Oncology, Eberhard Karls University Tuebingen, Germany
9. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
10. Cluster of Excellence iFIT (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Germany

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.12.03; Accepted: 2022.06.08; Published: 2022.07.18

Abstract

Background: Antibodies targeting surface expressed disialoganglioside GD2 are increasingly used in neuroblastoma immunotherapy and might also have potential for use in radioimmunotherapy. As such targeted treatments might benefit from a dedicated theranostic approach, we studied the influence of radiolabeling on the binding characteristics of ch14.18 antibodies produced by Chinese hamster ovary (CHO) cells and evaluated the benefit of GD2-ImmunoPET as a potential tool for therapy planning.

Methods: 64Cu was used to reduce radiation burden, which is of high importance especially in a pediatric patient population. 64Cu-labeling was accomplished using the chelators NOTA- or DOTAGA-NCS. Radiolabeled antibodies were characterized in vitro. [64Cu]Cu-DOTAGA-ch14.18/CHO was studied in a neuroblastoma mouse model (subcutaneous CHP-134 xenografts). In vivo PET and MR images were acquired at 3 h, 24 h, and 48 h p.i. The specificity of binding was verified using GD2-negative tumors (HEK-293 xenografts), a control antibody and in vivo blocking. A first translational application was performed by PET/MRI in a patient with metastasized neuroblastoma.

Results: Radiolabeling at an antibody-to-chelator ratio ≥1:10 yielded a product with a radiochemical purity of ≥90% and a specific activity of 0.2-1.0 MBq/µg. Radiochelation was stable over 48 h in PBS, mouse serum or EDTA, and 50.8 ± 3.5% and 50.8 ± 2.0% of the radiolabeled conjugates, prepared at antibody-to-chelator ratios of 1:10 or 1:15, were immunoreactive. In vivo, highly specific accumulation (31.6 ± 5.8% ID/g) was shown preclinically. Clinical PET/MR scans using [64Cu]Cu-NOTA-ch14.18/CHO (NOTA used for safety reasons) could visualize neuroblastoma metastases.

Conclusions: In vivo, 64Cu-labeled ch14.18/CHO is suitable for specific identification of neuroblastoma in PET. A first patient PET indicated the feasibility of the method for clinical translation and the potential utility in image-guided therapy.

Key words: neuroblastoma, GD2, PET, Immunelaging, theranostic

Background

Neuroblastoma (NB) is one of the most frequently occurring extracranial malignancies in early childhood. Although its outcome has improved, cure rates among children with high-risk NB remain poor. Currently, targeted immunotherapy represents a promising approach to improve the prognosis of
these patients [1, 2]. The disialoganglioside GD2, a tumor-associated antigen that is present in high levels on NB cells and other tumors of neuroendocrine origin, is one of the main targets of antibody-mediated treatments. Several anti-GD2 antibodies have been evaluated for use in immunotherapy [3] and in 2015, the chimeric antibody ch14.18 was approved for the clinical treatment of high-risk NB (Dinutuximab, Unituxin) [4]. This antibody, which is produced by SP2/0 murine myeloma cells, is not available in Europe; therefore, the production of ch14.18 in Chinese hamster ovary (ch14.18/CHO) cells was commissioned by the Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) [5]. Production of antibodies by CHO cells has the potential to reduce murine xenotropic retrovirus contaminations and results in an improved glycosylation pattern that helps avoid rapid clearance [5-9]. Clinical studies of this antibody were conducted and ch14.18/CHO showed no alterations in clinical activity, toxicity, or pharmacokinetic profile compared to other formats [9, 10]. Ch14.18/CHO was approved by the EMA in 2017 (Dinutuximab beta, Qarziba) [11] and even further GD2 directed antibody ch14.18/CHO showed no alterations in clinical activity, toxicity, or pharmacokinetic profile and ch14 .18/CHO showed no alterations in clinical studies [17]. Although GD2 is mainly considered to be ubiquitously expressed in NB, a loss either of the tumor-associated antigen that is present in high levels in these patients [1, 2].

In addition to immunotherapy, several studies investigated the feasibility of radioimmunotherapy (RIT) with the I-131 labeled GD2-specific antibody 3F8 in NB [13], as well as in medulloblastoma [14] and meningeal metastases [15]. As this radioimmunotherapy did not show a survival benefit compared to the treatment with unlabeled 3F8 in metastatic stage 4 NB patients, GD2 targeted RIT is still relatively rarely applied. Instead, radiolabeled metaiodobenzylguanidine (MIBG), which accumulates in catecholaminergic cells, is used in targeted NB radiotherapy ([131I]MIBG) [16]. As the identical molecule ([123I]MIBG) is applied for diagnostic imaging of NB using single photon emission tomography (SPECT), a theranostic approach is available.

A similar theranostic approach, enabling image-guided GD2 targeted therapies, could be beneficial and outperform earlier I-131 GD2 RIT studies [17]. Although GD2 is mainly considered to be ubiquitously expressed in NB, a loss either of the complete or partial GD2 expression is described in up to 12% of the cases [18]. Furthermore, the tumor uptake of antibodies is also dependent on various other factors like the perfusion or interstitial pressure of the tissue [19]. Therefore, theranostic imaging may improve the efficacy of GD2 targeted treatments by potentially allowing an estimation of antibody accumulation in the tumor lesions before start of treatment. Additionally, GD2 imaging could broaden the field of application for GD2 targeted therapy towards tumors with more variable GD2 expression e.g. melanoma or sarcoma and support more exploratory therapeutics like GD2 tumor vaccinations or GD2 CART-cells.

Several GD2 antibodies have already been radiolabeled in recent years. To translate initial SPECT studies [20, 21] to positron emission tomography (PET), investigators have conjugated long-lived positron emitters such as 64Cu (half-life 12.7h) to the GD2-specific antibodies hu14.18K322A and ch14.18/SP2/0. These conjugates were tested exclusively in preclinical mouse models [22-24] and therefore additional results are needed for the preparation of a prospective clinical study on GD2-ImmunPET.

As the therapeutic application of ch14.18 has been approved in the US and in the European Union, there might be high potential to use especially this antibody within a theranostic approach. For this reason, we studied the characteristics of 64Cu-labeled ch14.18/CHO [25] in vitro and in vivo to establish a tool towards PET based planning of GD2 immunotherapy but also to pave the way for the development of a combination of GD2-ImmunPET with GD2 directed RIT using e.g. Lu-177 within the same construct.

Radiolabeling was based on the bifunctional chelators p-NCS-Bn-NOTA (human study) and p-NCS-Bn-DOTAGA (animal studies). While DOTA is more versatile and also allows the use of other isotopes like Lu-177, NOTA derivatives reportedly yield higher in vivo stability for Cu-64 [26, 27]. Chelator conjugation and radiolabeling of ch14.18/CHO were evaluated in detail to optimize the conjugation protocol for clinical use. Target and off-target accumulation of the radioimmunoconjugate was quantified in vivo using immunodeficient CD-1 mice bearing subcutaneous NB xenografts from CHP-134 cells or GD2 negative control tumors from HEK-293 cells. In addition, a first translational approach was performed by assessing GD2 localization using this new radioimmunoconjugate in combined PET and magnetic resonance imaging (MRI), PET/MRI, in a patient suffering from NB before and after GD2 targeted therapy.

Methods

Cell Lines

The human GD2-expressing NB cell lines LS and CHP-134 were obtained from DSMZ (Braunschweig, Germany, ACC-675; ACC-653) and GD2-negative
human embryonic kidney cells (HEK-293) were purchased from ATCC (Manassas, VA, USA; CRL-1573, CRL-1435) shortly before the study. Both companies characterize cell lines based on short tandem repeat profiles. Throughout the project, the GDI2 expression of the cells was verified qualitatively using flow cytometry. All cells were cultured at 37 °C and 5% CO₂ in RPMI-1640 medium supplemented with penicillin (100 U/mL), streptomycin (100 mg/L), and 10% fetal calf serum (FCS; Biochrom GmbH, Berlin, Germany).

**Antibodies**

Ch14.18/CHO was produced by Rentschler Biotechnologie GmbH (Laupheim, Germany) and provided by APEIRON Biologies AG (Vienna, Austria). Antibody used for preclinical studies was for research use only, ch14.18/CHO used for human application was provided in GMP quality for active pharmaceutical ingredients (APIs). The chimeric CD19-specific control antibody 4G7SDIE [27] was produced by Celonic (Basel, Switzerland). Protein concentration was measured photometrically at 280 nm using a Nanodrop ND-1000 photometer (PeQLab, Erlangen, Germany) using IgG settings.

**Chelator Conjugation for Preclinical Studies**

Ch14.18/CHO was chelator-conjugated using the chelators p-NCS-Bn-DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)p entanedioic acid; Chematech, Dijon, France) and p-NCS-Bn-NOTA (2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid; Macrocyclics, Plano, TX, USA). During chelator conjugation, antibody-to-chelator ratios (ACR) of 1:15, 1:10, and 1:5 were used for p-NCS-Bn-DOTAGA labeling, and an antibody-to-chelator ratio of 1:15 was used for p-NCS-Bn-NOTA conjugation. For the control antibody 4G7SDIE the same chelators and procedures were used at an ACR of 1:15.

All buffers were treated with 1.2 g/L Chelex 100 (sodium form, Sigma-Aldrich, St. Louis, MO, USA) to avoid contamination with metals. For removal of metal contaminations ch14.18/CHO was pretreated with 2.8 mM EDTA for 30 min at room temperature (RT).

For p-NCS-Bn-DOTAGA conjugation, the buffer was exchanged to 0.1 M sodium bicarbonate pH 9 using Amicon Ultra-15 centrifugal filter units (three rounds of filtration) with a molecular weight cutoff of 30 kDa (Merck KGaA, Darmstadt, Germany). The chelator was dissolved in water at 10 mg/ml and added to the antibody (7.5 mg/ml, 440 µl per reaction) at the respective ACR. The conjugation reaction was conducted at RT for 1 h. Subsequently, the antibody was purified from excess chelator and buffered with 0.25 M sodium acetate pH 6 using an Amicon Ultra-15 centrifugal filter unit (seven rounds of filtration). Antibody integrity was measured before and after conjugation by HPSEC. The details of p-NCS-Bn-NOTA conjugation clinical tracer production are described in the respective section.

The number of chelators per antibody was assessed by mass spectrometry [28]. Briefly, the antibody samples were deglycosylated by overnight incubation with 1 U PNGase F (Hoffmann-La Roche AG, Basel, Switzerland) at 37 °C and subsequently reduced by the addition of 50 mM DTT (Sigma-Aldrich) and incubation for at least 10 min at 37 °C prior to chromatographic separation and mass spectrometry using electrospray ionization (ESI) on a LCT Premier mass spectrometer (Waters, Milford, MA, USA). Liquid chromatography (LC) was performed at a column temperature of 80 °C on an Aeris WIDEPORE XB-C18 column (3.6 µm, 100 mm x 2.1 mm; Phenomenex, Torrance, CA, USA) and a gradient of water, acetonitrile, and isopropanol over 20 min.

The obtained spectra were analyzed using MassLynx V4.1 and deconvoluted using the MaxEnt1 algorithm. The conjugation ratio Rc was calculated as $R_c = I_c / (I_c + I_{nc})$ *100%* with $I_c$ corresponding to the intensity of the conjugated and $I_{nc}$ of the unconjugated protein.

**Radiolabeling**

$^{64}$Cu was produced in a PETtrace cyclotron (16 MeV; GE Medical Systems, Uppsala, Sweden) by proton irradiation of $^{64}$Ni on a platinum/iridium plate (90/10) (30 mg, > 95% enrichment; Chemotrade Chemiehandelsgesellschaft mbH, Duesseldorf, Germany) and separated from metallic impurities by ion-exchange chromatography (AG1x8, Bio-Rad Laboratories, Hercules, CA, USA). Radiolabeling was performed according to a modification of a procedure that has been described in the literature [29]. Briefly, chelator-conjugated antibodies were incubated with 0.2-1 MBq $^{64}$CuCl₂ per µg for 1 h at 42 °C in 0.25 M sodium acetate buffer. Quality control was performed by thin-layer chromatography (TLC) using Polygram SIL G/UV 254 plates (Macherey-Nagel, Düren, Germany) and citrate buffer (tracer remained at baseline, observed Rf for unbound $^{64}$Cu of 0.2-0.8).

High-performance size-exclusion chromatography (HPSEC, BioSep SEC-s3000, Phenomenex; saline sodium citrate buffer, 1 ml/min) was used to check for fragmentation and aggregation of the antibodies.

To assess the release of $^{64}$Cu from the radiotracer, the radioimmunoconjugates were incubated with PBS, mouse serum (Life Technologies, Carlsbad, CA,
USA), or in presence of a competitor (ethylene-diaminetetraacetic acid (EDTA); Sigma-Aldrich) at 37 °C for a period of 2 days. TLC was performed repetitively (n = 1-3).

**In vitro Studies**

For *in vitro* experiments, adherent cells were detached using trypsin (Biochrom) and manually counted in a Neubauer-counting chamber after staining with trypan blue (Bio-Rad Laboratories). Neuroblastoma (CHP-134 or LS) or HEK-293 cells (1x10⁶ cells) were incubated in triplicate with 100 ng (ca. 67 kBq) of the radiolabeled antibody for 1 h at 37 °C. After the cells had been washed twice with PBS containing 3% bovine serum albumin (BSA; Sigma-Aldrich), the radioactivity in the cell pellets was determined by gamma counting using a Wizard² 2480 gamma counter (PerkinElmer Inc., Waltham, MA, USA) (n = 3-4, each in triplicate). Blocking studies were conducted by adding 10 µg of unconjugated antibody to the cells 30 min prior to incubation of the cells with the radiolabeled antibody (n = 4, each in triplicate).

The immunoreactivity of [⁶⁴Cu]Cu-DOTAGA-ch14.18/CHO was quantified using an assay developed by Lindmo et al. [30]. Briefly, increasing numbers of GD2-expressing LS cells (0.5-15 x 10⁶) were incubated with a constant amount of antibody (50-100 ng) as described above. By linear curve fitting of double inverse plots of 1/bound activity as a function of 1/cell count, the immunoreactive fraction (IF) was calculated (y-intercept; n = 3-4 per antibody). Nonspecific binding was measured using GD2-negative cells.

**Xenograft Models**

All animal experiments and housing conditions were approved by the regulatory authorities (Regierungsratspräsidium Tübingen; R10/16). Six-week-old CD1 nude mice (female) were purchased from Charles River Laboratories (Sulzfeld, Germany). The animals were housed in our vivarium under a 12/12 h light/dark cycle and were provided with food and water *ad libitum*. For tumor inoculation, 6 x 10⁶ HEK-293 or CHP-134 cells in 50% Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) were subcutaneously injected into the animals’ flanks. Experiments were performed when the tumors had reached a size of approximately 1 cm³.

**Preclinical in vivo Studies**

The *in vivo* biodistribution of the radiolabeled antibodies was assessed using an Inveon small-animal PET scanner (Siemens Preclinical Solutions, Knoxville, TN, USA). [⁶⁴Cu]Cu-DOTAGA-labeled antibody (12.25 ± 0.64 MBq, ACR 1:10) was injected intravenously into tumor-bearing mice (HEK-293+ch14.18/CHO: n = 7; CHP-134+ch14.18/CHO: n = 7; CHP-134+4G7SDIE: n = 7). Static 10 min PET scans and corresponding T2-weighted MR measurements were performed successively 3 h, 24 h, and 48 h after [⁶⁴Cu]-antibody injection (50 µg). For blocking, 500 µg of unconjugated ch14.18/CHO was injected 24 h prior to [⁶⁴Cu]Cu-DOTAGA-antibody administration (HEK-293+ch14.18/CHO: n = 4; CHP-134+ch14.18/CHO: n = 8; CHP-134+4G7SDIE: n = 4).

During measurements, the mice were anesthetized with 1.5% isoflurane (CP-Pharma Handelsgesellschaft mbH, Burgdorf, Germany) evaporated in isoflurane + oxygen mixture. The depth of anesthesia was monitored by breath frequency. MR measurements were performed immediately after the PET scans by transferring the animals on their beds to a 7-Tesla small animal MRI scanner (Clinscan, Bruker BioSpin GmbH, Rheinstetten, Germany). Anatomical structures were visualized by T2-weighted imaging consisting of a 3D-spoiled turbo spin echo sequence (256 x 161 matrix, 35 x 57 mm² FOV, TR = 3000 ms, TE = 205 ms, ST = 0.22 mm).

PET images were reconstructed using an ordered subset expectation maximization (OSEM-2D) algorithm. After manual fusion of reconstructed PET and MR images, volumes of interest were contoured based on MR information and tracer accumulation was analyzed using Inveon Research Workplace software (Siemens Preclinical Solutions). The results are expressed as percentage of the injected dose per volume (% ID/cc), tumor-to-muscle ratio (TMR), and tumor-to-liver ratio (TLR). After final imaging, an *ex vivo* biodistribution analysis was performed using the gamma counter. Decay-corrected radioactivity was normalized to organ weight: the results are expressed as % ID/g, TMR, TLR, and tumor-to-blood ratio (TBR).

**Tissue Staining**

After the last PET scan, tumor and muscle tissues were frozen in Tissue-Tek O.C.T. Compound (Sakura, Zoeterwonde, Netherlands), and 20 µm-thick cryosections were exposed to a phosphor screen (445SI, Molecular Dynamics, Sunnyvale, CA, USA) for 24 h. The autoradiographic results were read using a Storm 840 phosphorimager (Amersham Biosciences, Amersham, UK) and evaluated using ImageJ (National Institutes of Health, Bethesda, MD, USA). For comparison of different studies TMR was quantified. Following the autoradiography, the cryosections were stained with hematoxylin and eosin (H&E).

Additional tumors were fixed in formalin and embedded in paraffin (SAV-Liquid Production).
for stability analysis and patient safety. (validation syntheses), and other parameters required for target binding and stability (retrospectively): all tests were performed according to pharmacopoeia methods. Radiolabeled samples were tested in vitro for target binding and stability using the methods described above.

**Clinical Imaging**

Following the stipulations of the AMG §13(2b) a first-in-human PET/MRI scan with [64Cu]Cu-NOTA-ch14.18/CHO was performed in a 6 y/o NB patient suffering from bone metastases and diffuse bone marrow infiltration. The patient was referred to the experimental diagnostics unit by his pediatric oncologist, who was facing an unmet diagnostic challenge that could not be solved sufficiently using standard diagnostic means. The parents of the child participant provided written informed assent to the procedure on the child’s behalf. After bone marrow transplantation, the patient received three cycles of immunotherapy with 16-17 mg of ch14.18/CHO at intervals of 4-6 weeks.

One day prior to the first immunotherapy cycle and 18 days after the completion of the third cycle, both combined PET/MRI examinations were performed 24 h p.i. of 78 MBq [64Cu]Cu-NOTA-ch14.18/CHO (156 µg antibody, 3.7 MBq per kg body weight) on a whole-body PET/MRI system (Biograph mMR, Siemens Healthineers, Erlangen, Germany). PET images (6 min acquisition per bed position, 6 bed positions) were reconstructed using an OSEM-3D algorithm and corrected for scatter and attenuation using standard MR-based segmentation as described previously [32-35]. A coronal T1-weighted 3D-encoded spoiled gradient-echo sequence with double-echo for Dixon-based fat-water separation for attenuation correction, a coronal T2 turbo inversion recovery magnitude (TIRM), and transverse diffusion-weighted (DWI) echo-planar imaging sequences were acquired simultaneously to PET imaging.

[123I]MIBG SPECT/CT examinations were acquired 24 h p.i. of the radiotracer (96.9 and 101.4 MBq) according to clinical standards on a Discovery 670 Pro (GE Healthcare, Chicago, USA)
using a medium energy general purpose collimator. The SPECT images were reconstructed using an OSEM algorithm with 2 iterations and 10 subsets. Additionally, attenuation and scatter correction as well as resolution recovery were applied. SPECT/CT examinations were acquired 5 weeks before the first cycle of ch14.18/CHO therapy (baseline) and 2 days (follow-up) after the completion of the third cycle.

**Statistical Analysis**

Statistical analysis was conducted using a two-sided Student’s t-test; multiple-group comparisons were performed using a Tukey-Kramer test in Origin 8 software (OriginLab Corporation, Northampton, MA, USA). The data were considered significantly different when p ≤ 0.05. All quantitative results are presented as the mean ± 1 standard deviation.

**Results**

**Radiolabeling**

A schematic of the radiolabeling procedure is shown in Figure S1. Chelator-conjugated antibodies had an unchanged HPSEC elution profile as compared to the unconjugated antibody (Figure S2). Chelator-to-antibody ratios of 0.9, 1.2, and 1.4 were obtained for ch14.18/CHO conjugates to DOTAGA at ACRs of 1:5, 1:10, and 1:15 (Figure S3). For the DOTAGA-conjugated antibody, an RCP of ≥90% was routinely achieved when an ACR ≥1:10 was used. At smaller ACRs, unreliable labeling performance was observed depending on the quality of the 64Cu batch (DOTAGA 1:5 only up to 70%).

Stable radioconjugation was observed following incubation of the radioimmunoconjugates (DOTAGA-conjugated in at ACRs of 1:15 or 1:10) in PBS, serum, or EDTA. After 48 h, the radioconjugates retained > 80% of the original RCP in all buffers.

**In vitro Studies**

In a gamma counter assay, GD2-expressing cells (pooled data of CHP-134 and LS cells) exhibited strongly increased uptake of [64Cu]Cu-DOTAGA-ch14.18/CHO prepared at ACRs of 1:10 or 1:15 in comparison to controls (HEK-293 cells, control antibody: p < 0.001, Figure 1A). Blocking GD2 significantly reduced the cell-associated radioactivity for both GD2-specific radioimmunoconjugates (p < 0.01, Figure 1A).

In the Lindmo-assay the measured IFs of the radioimmunoconjugates were 50.8 ± 3.5% and 50.8 ± 2.0% for ch14.18/CHO-DOTA conjugates prepared at labeling ratios of 1:10 and 1:15, respectively (Figure 1B).

Due to the insufficient radiolabeling yield in combination with a lack of relevant increase in IF, ch14.18/CHO conjugated with an ACR of 1:5 was not analyzed further.

**Preclinical in vivo PET Imaging**

Over the time course of the in vivo PET study (Figure 2), [64Cu]Cu-DOTAGA-ch14.18/CHO reached a maximum tumor uptake of 14.2 ± 3.4% ID/cc and a TMR of 17.4 ± 3.6 48 h after tracer injection (Figure 2A/C). In comparison to GD2-negative tumors, NB uptake of ch14.18/CHO and its TMR was significantly higher at all time points examined (p < 0.001). Furthermore, accumulation of radiolabeled ch14.18/CHO in NBs significantly exceeded uptake of...
the radiolabeled control antibody, and its TMR was significantly higher (3 h, 24 h, 48 h: p < 0.001). In vivo blocking significantly reduced tumor uptake of $^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO to 2.4 ± 1.0% ID/cc, 6.2 ± 1.5% ID/cc, and 8.2 ± 1.4% ID/cc after 3 h, 24 h, and 48 h (p < 0.001, Figure 3). Furthermore, TLR (3 h, 24 h: p < 0.001, data not shown) and TMR (3 h, 24 h, 48 h: p < 0.001, Figure 3B) were decreased significantly.

The ex vivo biodistribution corresponded to an accumulation of $^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO of 31.6 ± 5.8% ID/g in CHP-134 NBs with a TMR of 30.2 ± 5.0 (Table 1, Figure 4A/B). The background accumulation in other organs remained below 8% ID/g. TLR was 4.4 ± 0.7, and TBR was quantified as 4.1 ± 0.6. $^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO showed a significantly lower accumulation of 6.9 ± 2.8% ID/g (p < 0.001) in GD2-negative tumors as well as significantly higher uptake in NB compared to the radiolabeled nonspecific control antibody (3.7 ± 0.7% ID/g, p < 0.001). After injection of 500 µg blocking antibody, tumor uptake (22.7 ± 2.0% ID/g) and TMR (20.1 ± 5.6) of the GD2-specific radioimmunoconjugate were significantly reduced (p < 0.005, Table 1, Figure 4C-E).

Table 1: Ex vivo biodistribution of radiolabeled antibodies. The ex vivo biodistribution of $^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO with and without blocking of GD2 using 500 µg unlabeled ch14.18/CHO 24 h prior to tracer administration was quantified 48 h after tracer injection. The distribution of a nonspecific control antibody (control ab) at 48 h is shown as a reference. Values are given in % ID/g.

<table>
<thead>
<tr>
<th></th>
<th>$^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO</th>
<th>$^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO -control ab</th>
<th>$^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO Block</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroblastoma</td>
<td>31.57 ± 5.79</td>
<td>3.71 ± 0.74</td>
<td>22.73 ± 1.95</td>
</tr>
<tr>
<td>Control tumor</td>
<td>6.94 ± 2.79</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Blood</td>
<td>7.81 ± 1.85</td>
<td>6.43 ± 1.64</td>
<td>7.95 ± 0.70</td>
</tr>
<tr>
<td>Heart</td>
<td>2.78 ± 0.39</td>
<td>2.98 ± 0.26</td>
<td>2.93 ± 0.50</td>
</tr>
<tr>
<td>Lung</td>
<td>5.79 ± 1.71</td>
<td>6.68 ± 2.51</td>
<td>5.66 ± 2.09</td>
</tr>
<tr>
<td>Liver</td>
<td>7.33 ± 1.44</td>
<td>12.17 ± 1.12</td>
<td>5.71 ± 0.80</td>
</tr>
<tr>
<td>Kidney</td>
<td>4.51 ± 0.87</td>
<td>5.91 ± 0.41</td>
<td>4.16 ± 0.74</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.06 ± 0.19</td>
<td>0.91 ± 0.07</td>
<td>1.20 ± 0.26</td>
</tr>
<tr>
<td>TMR (NB)</td>
<td>30.15 ± 5.00</td>
<td>4.08 ± 0.81</td>
<td>20.13 ± 5.56</td>
</tr>
<tr>
<td>TLR (NB)</td>
<td>4.37 ± 0.72</td>
<td>0.31 ± 0.08</td>
<td>4.07 ± 0.73</td>
</tr>
<tr>
<td>TBR (NB)</td>
<td>4.13 ± 0.62</td>
<td>0.60 ± 0.18</td>
<td>2.88 ± 0.28</td>
</tr>
</tbody>
</table>

Figure 2: In vivo PET imaging: Biodistribution of radiolabeled ch14.18/CHO. In vivo tumor uptake of $^{[64}\text{Cu}]$Cu-DOTAGA-labeled ch14.18/CHO and of the radiolabeled control antibody (control ab) is shown in % ID/cc for the three imaging time points and the tumor models CHP-134 (NB) and HEK-293 (ctrl) (A). Whole-body PET images display the distribution of the tracer at 3 h, 24 h, and 48 h after injection of radiolabeled ch14.18/CHO into NB-bearing mice (B). TMR for the same imaging time points is shown in (C). PET images acquired 24 h after tracer injection show the in vivo accumulation of $^{[64}\text{Cu}]$Cu-DOTAGA-ch14.18/CHO in NB in comparison with its uptake into control lesions and with the accumulation of the radiolabeled control antibody in NB (D). Tumors are indicated by arrows. Liver (L), heart (H) and kidneys (K) are indicated as reference. Significant differences at p < 0.001 are indicated by ***.
Figure 3: In vivo blocking study. In vivo NB uptake of [64Cu]Cu-DOTAGA-labeled ch14.18/CHO is shown in % ID/cc for animals that did or did not receive an injection of 500 µg unlabeled ch14.18/CHO 24 h prior to tracer administration to block GD2 (A). TMR is depicted for the same groups (B); both results indicate highly specific binding of [64Cu]Cu-DOTAGA-ch14.18/CHO in vivo. PET and MR images acquired 24 h after tracer application show reduced accumulation of the tracer in tumors after blocking (C). Tumors are indicated by arrows. Liver (L) and heart (H) are indicated for reference. Significant differences at p < 0.001 are indicated by ***.

Autoradiography of tumor (Figure 4E) and muscle as well as immunohistochemical staining to determine antibody distribution in the tumors (Figure 5A) supported these findings. After injection of 50 µg radiolabeled ch14.18/CHO, the NB xenografts demonstrated high signal intensity in autoradiography, and with immunohistochemistry clearly specific GD2 membrane staining was distributed through the whole tumor. The autoradiographic signal intensity was greatly reduced after blocking (Figure 4E). After [64Cu]Cu-DOTAGA-4G7SDIE injection, CHP-134 tumor slides showed only a low autoradiographic signal (Figure S4) and nonspecific background staining in immunohistochemistry (Figure 5A). HEK-293 tumor sections showed only background radioactivity signal (Figure S4) and staining (Figure 5A). GD2 expression was only observed in NBs (Figure S5). H&E and CD31 staining demonstrated the comparability of the tumors (Figure 5B). H&E staining of CHP-134 NBs and HEK-293 lesions showed large cells with irregular nuclei, open chromatin, and prominent nucleoli. CD31 immunostaining revealed blood vessels of variable caliber in both xenografts.

Preparation for Human Application

Although the preclinical imaging results were promising despite the use of a suboptimal chelator for 64Cu (DOTAGA), we decided to change the chelator to NOTA, which has a higher affinity to Cu. Especially in pediatric patients this minimizes the risk of unintended radiation exposure e.g. by free 64Cu uptake in the liver, kidneys or the bone marrow. This is also important in regards to the preparation of a prospective study investigating the diagnostic value of GD2-PET in Neuroblastoma patients.

Following the conjugation protocol described above, LC-MS analysis displayed successful conjugation of ca. 2.3 chelator molecules per antibody (Figure S3). Radiolabeling consistently yielded radiochemical purities of > 95% with a set specific radioactivity of 0.5 MBq/µg. All QC results met the specifications corresponding to the pharmacopeia requirements for radiopharmaceuticals. The radiochelation of NOTA-ch14.18/CHO was shown to remain consistent (RCP: 89.7%; 90.4%; 87.8% at 48 h post labeling after 2 days of incubation in PBS, mouse serum, or 2 mM EDTA; Figure S6). Furthermore,
[\textsuperscript{64}Cu]Cu-NOTA-ch14.18/CHO showed GD2-specific binding \textit{in vitro} (Figure S6).

\textbf{Clinical Imaging}

One day before the first cycle of immunotherapy with ch14.18/CHO, [\textsuperscript{64}Cu]Cu-NOTA-ch14.18/CHO PET (GD2-PET) indicated tracer accumulation in several lesions in a patient with metastatic NB. PET images most likely showed also an unspecific and perfusion-related tracer deposition in the blood pool, as well as in unaffected organs and bone marrow (especially in the spine; Figure S7). Thus, for better visualization of NB metastases and differentiation of the metastases from the unspecific uptake in bone marrow, an adapted windowing of the PET images was used, whereby the windowing was adjusted to a lower threshold of SUV 0.5 in order to minimize the visible unspecific background signal (PET 0.5; Figure 6A/B).

PET images revealed the highest uptake of the radiolabeled antibody in the right femur (Figure 6A left panel, white arrows). Corresponding MRI and [\textsuperscript{123}I]MIBG SPECT/CT (Figure 6A right panel) scans performed 5 weeks prior to PET identified lesions corresponding to the findings in GD2-PET. Furthermore, [\textsuperscript{123}I]MIBG SPECT/CT revealed an additional diffuse bone marrow infiltration especially in the pelvis and in the lower extremities which were only hinted provable in GD2-PET after an adapted windowing was applied (PET 0.5).

In the follow-up GD2-PET performed 18 days after the third therapeutic cycle of ch14.18/CHO antibody, some of the lesions showed reduced accumulation of the radiolabeled antibody compared to the baseline scan (Figure 6B left panel, green arrows); in particular the uptake in the femoral lesion was demonstrably reduced. The same lesions indicated treatment response according to MRI and [\textsuperscript{123}I]MIBG findings (Figure 6B right panel, green arrows). However, additional new bone metastases were detected in the second GD2-PET (Figure 6B left panel; red arrow; exemplary lesions), which were confirmed by MRI (Figure 6B right panel; whole-body TIRM) and planar [\textsuperscript{123}I]MIBG scintigraphy (Figure 6B; right panel). Though, some new bone lesions that were indicated by [\textsuperscript{123}I]MIBG scintigraphy and MRI were not detectable by GD2-PET (Figure 6B, black arrows). The diffuse bone marrow infiltration in the [\textsuperscript{123}I]MIBG SPECT/CT was almost completely diminished after therapy, while still detectable antibody uptake was found in the bone marrow in GD2-PET suggesting potential the bone marrow infiltration (e.g. femur and tibia, both sides).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{\textbf{Ex vivo biodistribution.} At 48 h after in vivo tracer uptake, the biodistribution of [\textsuperscript{64}Cu]Cu-DOTAGA-ch14.18/CHO and that of a radiolabeled control antibody (control ab) in diverse organs \textit{ex vivo} were quantified using a gamma counter. Uptake values are given in \% ID/g for NB and HEK-293 tumor-bearing animals (A) and for NB-bearing animals after blocking GD2 with unlabeled ch14.18/CHO (C). The results verified the specificity of the GD2 targeting tracer. The tumor-to-organ ratios TMR, TLR, and TBR observed in both studies are shown (B/D). Autoradiography (upper panel) supported the findings, H&E stainings of the autoradiography slides are shown for comparison (lower panel); a representative animal from the blocking study is shown (E). Significant differences at $p < 0.01$ or $p < 0.001$ are indicated by ** or ***, respectively.}
\end{figure}
Figure 5: Histology and immunohistochemistry of xenografts. Immunohistochemical staining of tumor sections revealed specific uptake of $[^{64}\text{Cu}]\text{Cu-DOTAGA-ch14.18/CHO}$ in NBs 48 h after tracer injection (A). After injection of $[^{64}\text{Cu}]\text{Cu-DOTAGA-ch14.18/CHO}$ into NB-bearing animals, tumors showed clearly positive staining (left panel). Controls (GD2-negative tumors; ctrl and control antibody; ab) showed only a slight background signal (middle and right panels). H&E staining of CHP-134 and HEK-293 lesions revealed large cells with irregular nuclei, open chromatin and prominent nucleoli. CD31 immunostaining indicated blood vessels of variable caliber in both xenografts (B).

Discussion

The use of GD2-specific antibodies in NB immunotherapy has been studied extensively and a few antibodies have already found their way into clinical routine [3, 22, 23, 36]. Similar to most other targeted therapies, a major challenge of current GD2 targeting immunotherapies is the individual response to therapy and the lack of adequate predictive markers [37]. In this regard, radiolabeled antibodies have a high potential as they might be applied for guidance of these complex therapeutic approaches using the same antibody for imaging and subsequent (radio)immunotherapy. Recently, Bensch et al. impressively demonstrated the potential of such a theranostic approach by correlating the accumulation of a radiolabeled antibody against programmed death ligand 1 (PD-L1) in tumors with the therapeutic response to immune checkpoint blockade and showed the superiority of this method to standard histological evaluation of PD-L1-expression in the initial tumor biopsy [38].

Here, we studied the in vitro and in vivo characteristics of $^{64}\text{Cu}$-labeled ch14.18 produced in CHO cells (Dinutixumab beta) to establish a tool towards PET based planning of GD2 directed immunotherapy but also to pave the way for the development of a theranostic combination of $^{64}\text{Cu}$ imaging and GD2 targeting radioimmunotherapy within the same construct. GD2 imaging could furthermore broaden the field of application for GD2 directed therapy towards tumors with more variable GD2 expression e.g. melanoma or sarcoma and support more exploratory therapeutics like GD2 tumor vaccinations or GD2 CART-cells.
First-in-human GD2-PET/MR scans were performed after application of $^{64}$Cu-NOTA-ch14.18/CHO in a 6 y/o patient suffering from metastatic neuroblastoma prior to and after therapeutic application of ch14.18/CHO. To better distinguish between metastasis and the unspecific uptake in the bone (especially in the spine and the pelvis) the windowing was adapted to a lower threshold of SUV 0.5 in order to minimize the visible background signal (PET 0.5; see Figure S7A). A: Positive $^{64}$Cu-NOTA-ch14.18/CHO foci were found in several lesions (as indicated by arrows) on coronal fused PET/MRI and PET-MIP images. Simultaneous MRI (whole-body T2 TIRM) and planar $^{[123]}$I-MIBG scintigraphy (five weeks prior to GD2-PET/MRI) revealed diffuse bone marrow infiltration as well as bone metastases corresponding to the GD2-positive lesions. B: Follow-up GD2-PET/MRI 2.5 weeks after the 3rd therapeutic application and 3 months after initial PET/MRI indicated a mixed response to anti-GD2 therapy. Treatment response was observed in some lesions (green arrows), e.g., in the right femur. In addition, several progressive as well as new bone metastases (red arrow, exemplary lesions) were detected after therapy. MRI (whole-body T2 TIRM) and planar $^{[123]}$I-MIBG scintigraphy (2.5 weeks before GD2-PET/MRI, 2 days after completion of the third cycle) confirmed progressive disease but also identified additional lesions (examples, black arrow) that were not detected by GD2-PET.

After a thorough preclinical in vitro and in vivo evaluation of the benefit of $^{64}$Cu-labeled ch14.18/CHO for NB diagnostics, a first translational approach involving its compassionate use in an individual patient suffering from NB was performed. We decided to use $^{64}$Cu, instead of e.g. $^{89}$Zr as radiolabel for the anti-GD2 antibody in order to keep the radiation dose for the patients low, which is of high importance especially in a pediatric patient population [39]. We believe, $^{64}$Cu still allows sufficient uptake time, specifically if the images are intended to be applied for treatment planning.

Our data demonstrate the feasibility of $^{64}$Cu-labeling of the GD2-specific antibody ch14.18/CHO using the chelators DOTAGA-NCS and NOTA-NCS. Although chelator conjugation and radiolabeling were conducted under mild conditions and we achieved moderate chelator numbers per antibody, the IF of the radiolabeled GD2-specific antibodies were below 60%. In the applied assay
set-up, the apparent IFs might be influenced by rapid shedding of GD2 from target cells, leading to blockage of the radiolabeled antibody and reduction of the obtained value of the IF [40]. However, as Voss et al. also revealed an IF of only 70% for radiolabeled ch14.18 using immobilized GD2 [22], the low cell surface reactivity might also be influenced by modification of an accessible amino acid either within or close to the antigen binding site of ch14.18/CHO and its related antibodies. Indeed, CDR2 of the parental 14G2a light chain contains a lysine residue at position 55 that is involved in recognition of GD2 [41]. Consequently, lysine coupling might not be ideal for radiolabeling GD2-specific antibodies, and further investigation of linker chemistry or purification of the radiolabeled antibodies might be helpful in improving the quality of GD2-specific radioimmunoconjugates. The use of derivatives such as maleimide DOTA or NH2-DOTA-GA offers other potential conditions for conjugation [42, 43] that might minimize the loss of immunoreactivity. Vavere et al. [23] radiolabeled the humanized variant of ch14.18 (hu14.18K322A) using p-NH2-Bn-DOTA, which binds to glutamic acid residues and showed that target binding is retained. The same group also used p-SCN-Bn-NOTA to radiolabel hu14.18K322A [24], unfortunately for both immunoconjugates the immunoreactive fraction is not reported or compared. Nevertheless, also other conjugation strategies could reduce immunoreactivity as binding site of ch14.18/CHO also contains glutamic and aspartic acid (heavy chain E101, D52). Thus, additional conjugation routes and quality control assays have to be explored in future work.

In our preclinical in vivo PET studies, [64Cu]Cu-DOTAGA-ch14.18/CHO revealed high tumor accumulation with a %ID/g of 31.6 ± 5.8; this is at least on par with other radiolabeled antibodies such as HER2/neu-specific trastuzumab [44] and EGFR-specific cetuximab [45]. The difference of a factor 2–2.5 that was observed between in vivo and ex vivo quantification is a phenomenon that has been described previously and is mainly caused by the influence of different complex factors including scatter and its correction methods, attenuation as well as the partial volume effects in the reconstructed VOI, while the gamma counter is not influenced by this as it does not involve any information about spatial distribution of the measured radioactivity [46, 47]. However, for the scope of this manuscript the relative differences between the NB and the control tumors as well as the blocked and the non-blocked experimental animals is more important. These relative differences are largely consistent throughout both methods. Although the immunoreactivity of our antibody seemed to be impaired by radiolabeling, both the NB uptake of ch14.18/CHO and the TMRs significantly exceeded the values obtained for the control antibody, indicating specific tumor uptake of [64Cu]Cu-DOTAGA-ch14.18/CHO. In vivo blocking studies and the significant difference in NB to control tumor uptake of the radiolabeled antibody further support its in vivo specificity. Full tumor saturation was not reached by the blocking dose, however as the blocking experiment was performed to verify specificity, titration of the full blocking dose was not in scope of this manuscript.

In a study by Voss et al., [64Cu-SarAr]-labeled ch14.18 showed a lower xenograft uptake compared to our findings, although the reported IF was higher [22]. However, tumor accumulation is highly influenced by tissue characteristics such as target expression [24], interstitial pressure [48], vessel leakage [49], and necrosis [50, 51], and potential differences in these characteristics decreases the comparability of different tumor models.

To facilitate translation to the clinic and to allow for labeling with therapeutic isotopes such as 177Lu, DOTAGA, a derivative of DOTA which is widely used as a chelator in clinical radiopharmaceuticals, was used in our preclinical studies. However, a reported disadvantage of the use of DOTA derivatives is the loss of copper in vivo with subsequent accumulation of unbound activity in the liver [52]. Beside the liver, free 64Cu is accumulating in muscle, kidneys as well as to a lesser extent in the red bone marrow of patients revealed by PET imaging with [64Cu]CuCl2 [53]. For safety reasons, we radiolabeled ch14.18/CHO with NOTA for the first patient [26, 54], which has been reported to have increased complexation stability for 64Cu compared to DOTA and is also used clinically.

In addition to NOTA, many other bifunctional chelators have been examined in preclinical studies to e.g. improve stability [22, 54]. For instance, ch14.18 has previously been radiolabeled using the newly designed chelator 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaaazabicyclo[6.6.6]-eicosane-1,8-diamine (SarAr), which is based on a diamsar ligand [22, 55]. However, the lack of human safety data for SarAr precludes its immediate clinical translation. Furthermore, diamsar-based chelators and smaller chelators such as NOTA are not suitable for use with complex radionuclides with larger diameters such as 177Lu [42], which is disadvantageous in regards of our future aim to evaluate the combination of 64Cu-ImmunoPET and 177Lu based radioimmunotherapy.

All of the radioconjugates prepared in our study showed high stability in vitro and preclinically less than 8% of the injected activity was found per gram.
liver in the used experimental tumor models in vivo, a level that is comparable to the liver accumulation that was quantified for ch14.18 radiolabeled using SarAr. For this reason, we believe that DOTAGA-labeled GD2-specific antibodies are currently an adequate choice for the development of clinical approaches, especially when their use in radioimmunotherapy is the primary goal.

In our first translational approach, a patient suffering from NB metastases was investigated by [64Cu]Cu-NOTA-ch14.18/CHO PET/MRI before and after immunotherapy. Through the use of ImmunoPET we were able to identify NB metastases and potentially to predict their response to immunotherapy, as well as to detect disease progression confirmed by the clinical standard methods MRI and [123I]MIBG scintigraphy. In addition to NB uptake, our PET data indicate presence of [64Cu]Cu-NOTA-ch14.18/CHO in the blood pool as well as most probably a perfusion-dependent accumulation in different organs and bone marrow which is in line with the distribution of other antibody constructs [38, 56]. As this background accumulation might reduce the sensitivity in lesion detection, later imaging e.g. at 48 h will be evaluated in the future. The choice of 24 hours after injection for imaging is based on our preclinical findings and on a practicable clinical workflow, especially for the diagnosis of children. Allowing a slightly longer uptake time between injection and imaging might decrease the amount of radioactivity in the blood and would still be possible with 64Cu. Smaller GD2-specific constructs, such as antibody fragments, might have better accessibility and would allow for earlier imaging; however, for our aim of enabling image-guided immunotherapy it was essential to use exactly the same biological substance in imaging and therapy.

Interestingly, a femoral lesion with prominent [64Cu]Cu-NOTA-ch14.18/CHO uptake in the baseline scan showed strong response to immunotherapy as assessed by MRI and [123I]MIBG scintigraphy after the third treatment cycle. The high uptake of the radiolabeled antibody at baseline might indicate very good accessibility of the therapeutic antibody to the lesion and an increased likelihood of response to the treatment. On the contrary, there was a lack of uptake of the radiolabeled antibody by other lesions identified in [123I]MIBG scans or the MRI at baseline. In reverse conclusion, this finding possibly indicates restricted access to the therapeutic antibody and potentially gives very valuable predictions regarding a limited treatment efficacy of a corresponding immunotherapy. Potential reasons for a lack of accumulation might be a reduction in GD2 expression or restriction of access due to perfusion or diffusion effects. In addition, the use of a non-optimal dose of the radiolabeled antibody might decrease its accumulation [56]; thus, a phase I dose escalation clinical trial is needed. Furthermore, the potential impact of the time interval between the [123I]MIBG and GD2-PET scans must be considered.

Follow-up GD2-PET scanning was performed 2.5 weeks after the last treatment with the therapeutic antibody to verify the imaging capabilities of [64Cu]Cu-NOTA-ch14.18/CHO and to compare signs of response in GD2-PET to standard methods. At this time point, the femoral lesion showed a reduced uptake of [64Cu]Cu-NOTA-ch14.18/CHO. Saturation of GD2 receptors is unlikely since the antibody has a half-life of 3.2 days in serum [9]. Treatment antibody bound to the tumor significantly after the unbound antibody is cleared from the blood at the time of the follow up study is unlikely due to target turn over, shedding and internalization. As we see also lesions with increasing [64Cu]Cu-NOTA-ch14.18/CHO uptake in the follow-up PET compared to the baseline study, blocking might not explain the decreasing uptake in the lesions e.g. in the right femur.

The identification of non-responding lesions that were detected at baseline or of new lesions in a follow-up GD2-PET after treatment might indicate an insufficient treatment dose or disease progression. Thus, in image-guided immunotherapy, it is important to choose the right therapeutic dose [57], identify potentially inaccessible lesions and optimize the time points during the course of disease for therapeutic antibody application [58].

The appearance of lesions in the [123I]MIBG or MRI scans but not in the GD2-PET scan should be further addressed in prospective clinical studies. Although [123I]MIBG reveals NB with limited sensitivity, its specificity is high [59]. T2-weighted MRI exhibits a high sensitivity of detection of NB but a low specificity, although this might be improved by the use of diffusion weighted (DW) MRI. Thus, GD2-PET could potentially be useful not only for guiding antibody-based GD2 immunotherapy but also in combination with DW-MRI to improve the sensitivity and specificity of detection of NB lesions.

Conclusion

The focus of our study was the establishment of dedicated theranostic imaging for GD2 directed treatments with the ultimate goal of guiding therapy for NB. Using the clinically approved antibody ch14.18/CHO, we developed a chelator- and radiolabeling protocol with immediate translational potential and produced a radioimmunoconjugate that shows specific tumor targeting in vivo, high NB uptake, and low background accumulation. Finally,
the potential clinical relevance of GD2-ImmunoPET was shown in a first-in-man compassionate use imaging trial. Without doubt, larger trials are needed to explore the clinical characteristics and limitations of this approach. However, these first results provide insight into a new method that offers the potential for *a priori* treatment response estimation for GD2 directed (radio)immunotherapy.

**Abbreviations**

ACR: antibody-to-chelator ratios  
AMG: Medicinal Products Act (“Arzneimittelgesetz”)  
BSA: bovine serum albumin  
CHO: chinese hamster ovary cells  
DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid  
DOTAGA: 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanediolic acid  
DTPA: diethylenetriaminepentaacetic acid  
DTT: dithiothreitol  
DWI: transverse diffusion-weighted imaging  
EDTA: ethylenediaminetetraacetic acid  
ESI: electrospray ionization  
FCS: fetal calf serum  
GMP: good manufacturing practice  
H&E: hematoxylin and eosin  
HEK-293: human embryonic kidney cells  
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HPSEC: high performance size exclusion chromatography  
ID/cc: injected dose per cubic centimeter  
IF: immunoreactive fraction  
LC: liquid chromatography  
MIBG: metaiodobenzylguanidine  
MRI: magnetic resonance imaging  
NB: neuroblastoma  
NCS: isothiocyanate  
NOTA: 1,4,7-triazacyclononane-1,4,7-triacetic acid  
PET: positron emission tomography  
RCP: radiochemical purity  
RT: radioimmunotherapy  
RT: room temperature  
SarAr: 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine)  
SIOPEN: Society of Pediatric Oncology European Neuroblastoma Group  
SPECT: single-photon emission computed tomography  
TBR: tumor-to-blood ratio  
TIRM: T2 turbo inversion recovery magnitude  
TLC: thin-layer chromatography  
TLR: tumor-to-liver ratio  
TMR: tumor-to-muscle ratio

**Supplementary Material**

Supplementary figures.  
https://www.thno.org/v12p5615s1.pdf

**Acknowledgements**

We thank St. Jude Children's Research Hospital for providing hu14.18K322A and Prof. G. Jung for providing the 4G7SDIE clone. Further we thank Hans Loibner (Apeiron Biologicals) for supplying the antibody. We thank Sandro Aidone, Walter Ehrlichmann, Ramona Stumm, Natalie Mucha, Ursula Kohlhofer and Irene Gonzalez-Mendez for technical assistance.

**Funding**

This research was funded by the Werner Siemens Foundation, the Institutional Strategy of the University of Tuebingen (Deutsche Forschungsgemeinschaft, DFG, ZUK 63), the German Cancer Consortium (DKTK) as well as the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy - EXC 2180 – 390900677. We thank the Gesellschaft für Kinderkrebsforschung Geltendorf, the Stiftung für krebserkrankte Kinder e.V Tuebingen and the Stefan-Morsch Stiftung Birkenfeld for supporting the clinical grade production of ch14.18.

**Author contributions**

J.S., R.H. and B.J.P. conceived and designed the research. J.S., M.P. and D.S. acquired the preclinical PET/MR data, performed the *in vitro* studies and analyzed the *in vivo* imaging and the *in vitro* data. J.S., M.A.K, R.H. and B.J.P. supervised the study and interpreted the results. A.M. developed conjugation and radiolabeling of the antibodies. G.R. developed copper production, radiopharmaceutical preparation and quality assurance for human application. J.E.W. performed LC-MS chelator quantification. L.Q.-M. directed the histological and immunohistochemical analysis. S.D.G., R.H. supported the production and availability of the antibody. J.Schw., C.I.F, and J.F.S. performed, analyzed and interpreted the clinical data. All authors edited the manuscript and have given approval to the final version of the manuscript.

**Ethics approval and consent to participate**

The personalized diagnostic procedure was performed as compassionate use according to the regulations of the German medicinal products act (“Arzneimittelgesetz”; AMG §13(2b)), for which no distinct ethical approval is needed. The parents of the child participant provided written informed consent to the procedure on the child’s behalf. The retrospective analysis of PET data was approved by
the ethics committee of the University of Tübingen (416/2015R).

Consent for publication

The parents of the child participant agreed with the scientific analysis and publication of the anonymized clinical data.

Availability of data and material

The data generated and analyzed in this manuscript is not publicly available due to proprietary restrictions but may be available from the corresponding author on reasonable request.

Competing Interests

J.S. is now an employee of Boehringer-Ingelheim Pharma GmbH & Co. KG, the work was part of her PhD thesis at the University of Tuebingen. J.F.S receives grant/research support from: Siemens, and Bayer Healthcare; however, none of the grants are directly related to this work.

C.I.F. receives grant/research support from: Oncovision, GE, and Siemens; however, none of the grants are directly related to this work.

B.J.P. receives grant/research support from: Bayer Healthcare, Boehringer-Ingelheim, ImaginAb, Oncodesign, Bruker, and Siemens; however, none of the grants are directly related to this work.

M.F. is now employee of Foundation Medicine, the work was part of his Master’s Thesis at the University of Tuebingen.

S.D.G. is an employee of Provenance Biopharmaceuticals Corp.


References


